The article "The global burden of fatty liver disease: the major impact of China" by Tian-Wen Lou, Rui-Xu Yang, and Jian-Gao Fan reviews the global and Chinese epidemiology of nonalcoholic fatty liver disease (NAFLD) and its associated conditions. The prevalence of NAFLD has been increasing globally due to factors such as energy-dense diets, sedentary lifestyles, and an aging population. In Europe and the United States, NAFLD is the second leading cause of end-stage liver disease and liver transplantation. The global prevalence of NAFLD is estimated at 32.4%, with higher rates in men and significant variations across regions, particularly in Latin America and the Middle East. In China, the overall prevalence of NAFLD over the past 20 years has been 29.6%, with higher rates in men and older age groups. The incidence of NAFLD has been increasing over time, and it is significantly higher in obese and diabetic patients. The prevalence of NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD) is also increasing in children, with boys and overweight/obese children being more prone to developing NAFLD. The authors emphasize the critical need for public health campaigns and collaboration among hepatologists and other stakeholders to address the growing burden of NAFLD, which is currently underrepresented in national and international strategies for noncommunicable diseases. Effective measures are essential to prevent the disease from continuing to rise at an alarming rate.The article "The global burden of fatty liver disease: the major impact of China" by Tian-Wen Lou, Rui-Xu Yang, and Jian-Gao Fan reviews the global and Chinese epidemiology of nonalcoholic fatty liver disease (NAFLD) and its associated conditions. The prevalence of NAFLD has been increasing globally due to factors such as energy-dense diets, sedentary lifestyles, and an aging population. In Europe and the United States, NAFLD is the second leading cause of end-stage liver disease and liver transplantation. The global prevalence of NAFLD is estimated at 32.4%, with higher rates in men and significant variations across regions, particularly in Latin America and the Middle East. In China, the overall prevalence of NAFLD over the past 20 years has been 29.6%, with higher rates in men and older age groups. The incidence of NAFLD has been increasing over time, and it is significantly higher in obese and diabetic patients. The prevalence of NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD) is also increasing in children, with boys and overweight/obese children being more prone to developing NAFLD. The authors emphasize the critical need for public health campaigns and collaboration among hepatologists and other stakeholders to address the growing burden of NAFLD, which is currently underrepresented in national and international strategies for noncommunicable diseases. Effective measures are essential to prevent the disease from continuing to rise at an alarming rate.